Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. A New Avenue for the Long-Term Upstream Inhibition of the Renin-Angiotensin-Aldosterone System by Inhibiting Angiotensinogen RNA.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026
   Review
2. Hypertension and Heart Failure: From Pathophysiology to Treatment.International journal of molecular sciences · 2024
   Review
3. Novel antihypertensive agents for resistant hypertension: what does the future hold?Hypertension research : official journal of the Japanese Society of Hypertension · 2022
   Review
4. Clinical observation of sacubitril valsartan sodium in the treatment of resistant hypertension: A randomized clinical trial.Frontiers in cardiovascular medicine · 2022
   Article
5. The Natriuretic Peptides for Hypertension Treatment.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2022
   Review
6. Targeting Cyclic Guanylate Monophosphate in Resistant Hypertension and Heart Failure: Are Sacubitril/Valsartan and Vericiguat Synergistic and Effective in Both Conditions?High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2021
   Article

Corrections and comments

• Comment on
  Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.2021

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as